Kornimate/medical-research-clean huggingface dataset:
value of d-dimer combined with other thrombus molecular markers in risk assessment of vte in hospitalized patients

Conditions: Venous Thromboembolic Disease

Summary: the occurrence of vte in hospital is an important cause of unexpected death of inpatients, and has become a serious problem faced by hospital managers and clinical medical staff.under the target of "improving the standard prevention rate of venous thromboembolism" proposed in the "national medical quality and safety improvement goal in 2022", it is urgent to establish a highly sensitive vte risk assessment and monitoring system.at present, vte risk assessment scale is used for risk screening and monitoring in combination with d-dimer in clinical practice, but d-dimer has low specificity and poor sensitivity, which makes it impossible to accurately assess the risk of venous thrombosis.therefore, it is very important to explore highly specific molecular markers of thrombosis for vte risk assessment.this project will analyze the value of single or combined detection of different thrombus molecular markers in vte risk assessment, establish the best vte risk assessment scheme, improve the standardized prevention of vte, realize the early intervention of vte, truly achieve early detection, early prevention and early treatment, and effectively reduce the occurrence of vte.

this project is intended to explore the specificity and reliability of single or combined detection of different thrombus molecular markers in venous thrombosis risk assessment by detecting and analyzing the levels of various thrombus molecular markers in vte high-risk patients, so as to establish the best evaluation strategy for early identification of vte high-risk patients, build the hospital vte early warning management system, guide the clinical to formulate targeted graded intervention measures, and effectively reduce the occurrence of vte. at the same time, it will provide support for the realization of "improving the standard prevention rate of venous thromboembolism" proposed in the national medical quality and safety improvement goal in 2022 and reducing medical risks.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * surgical inpatients * patients who were assessed as high-risk by venous thrombosis risk assessment after admission (caprini score ≥5) * did not receive anticoagulation or thrombolysis before admission * patients without chronic cardiovascular disease, autoimmune disease, malignant tumor and other diseases * patients without previous history of venous thrombosis of lower limbs * the molecular markers of thrombus were detected routinely at admission * the family members of the patients signed informed consent exclusion criteria: * abnormal coagulation function due to blood disease or severe liver and kidney dysfunction * patients with major trauma or vegetative survival within 3 months * patients with long-term use of anticoagulant drugs, glucocorticoids and hemostatic drugs

Keywords: d-dimer thrombus molecular markers venous thromboembolism risk assessment
a trial of endostar in combination with chemotherapy of df and sequential intensity modulated radiation therapy for patients with advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Neoplasms

Summary: among all the head and neck tumors, nasopharyngeal carcinoma (npc) has a high tendency of recurrence and metastasis. for the advanced npc patients, chemoradiotherapy is the main way of treatment. currently, chemotherapy with cisplatin (ddp) combines with 5-fluorouracil (5-fu) is the classic front line therapy for npc. however, the abnormal richness of angiogenesis of tumor and blood supply in tissue caused by radiation therapy often decrease the effects of radiochemotherapy. human recombinant vascular endothelial inhibitor (endostar) can improve the sensitivity to chemoradiation via selectively inhibiting the migration of endothelial cells and the formation of tumor vessels. moreover, it would induce vascular remodeling and normalization of the tumor vasculature, which will effectively aid the delivery of oxygen and anticancer drugs. in sum, antiangiogenesis in combination with chemoradiotherapy will be a promising way of treatment for npc. in this study, the first-treated patients with npc (stage ⅲ or ⅳa) confirmed by pathology, and patients with recurrent and metastatic npc will be randomly assigned to two groups (1:1): a trial group (ddp, 5-fu, endostar and sequential intensity modulated radiation therapy (imrt)), and a control group (ddp，5-fu and sequential imrt). evaluations will be developed including progression-free survival (pfs), overall response rate（orr）, overall survival (os), adverse effects rate and quality of life. this research will provide more evidences of evidence-based medicine for the safety and tolerability of endostar and the clinical application of endostar in npc treatment.


Eligibility criteria:
inclusion criteria: * age from 18 to 70 ears ; * eastern cooperative oncology group performance status of 0-1; * diagnosed with first-treated npc (ⅲ/ⅳa stage) confirmed by pathology; * ecurrent and metastatic npc with indication of chemoradiotherapy; * one measurable lesion at least (according to the recist guidelines, the lesion iameter≥20 mm with mri); * life expectancy of ≥ 12 weeks; * adequate hematologic, renal, cardiac and liver function; * hemameba≥4.0×109/l; * neutrophil≥2.0×109/l; * platelet≥100×109/l; * hemoglobin≥95g/l; * serum bilirubin, alt and ast ≤1.5 times of maximum criteria; * sufficiently understand this study situation and signed the informed consent. exclusion criteria: * allergy or intolerance to study drugs; * receiving other anti-cancer therapy; * uncontrolled central nervous system lesions; * dysfunction of important organs； * history of cardiovascular disease(including congestive heart-failure, uncontrolled arrhythmia, angina pectoris which require long-term drug treatment, lular heart disease, myocardial infarction and resistant hypertension); * pregnancy or lactation in women; * protracted infective wound; * history of mental illness which is not easy controlled.
qva149 versus fluticasone/salmeterol in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (qva149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to severe copd.


Eligibility criteria:
inclusion criteria: * smoking history of at least 10 pack years * diagnosis of chronic obstructive pulmonary disease (copd) (moderate-to-severe as classified by the global initiative for chronic obstructive lung disease \[gold\] guidelines, 2009) * post-bronchodilator forced expiratory volume in 1 second (fev1) \>40% and \< 80% of the predicted normal value and post-bronchodilator fev1/forced vital capacity (fvc) \<70% exclusion criteria: * patients who have had a copd exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last year. * patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia. * patients who have had a respiratory tract infection within 4 weeks prior to visit 1. * patients with concomitant pulmonary disease * patients with a history of asthma * any patient with lung cancer or a history of lung cancer (within last 5 years) * patients with a history of certain cardiovascular co-morbid conditions

Keywords: qva149 indacaterol nva237 copd fluticasone/salmeterol
ehealth partnered evaluation initiative - evaluation of the initial deployment of va's annie texting system

Conditions: Hepatitis C

Summary: conduct a rigorous formative evaluation of the initial deployment of the annie texting system across several pilot test sites and from these findings, develop and test an augmented implementation strategy to facilitate more rapid adoption of annie across va.

the investigators examined patient and provider experiences with va's automated text messaging system, named "annie". the investigators aimed to describe early experiences using annie and subsequently pilot and evaluate an augmented implementation strategy to improve implementation of the system. then, seven new facilities implemented annie. the investigators focused on specialty clinics serving patients with hepatitis-c virus (hcv). working in collaboration with clinical team members and other office of connected care stakeholders, the investigators developed a texting protocol for veterans with hcv that included motivational messages, medication and lab appointment reminders. this protocol was made available to the seven new facilities. four facilities were randomized to serve as intervention sites to receive augmented implementation strategy. these facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance, described below. an additional three comparison sites received usual implementation of annie only, which involves an orientation/training meeting and the option of attending twice-monthly annie clinical adoption calls run by the office of connected care. two control sites did not receive annie. the investigators conducted a mixed-methods evaluation including pre and post patient and provider surveys and semi-structured interviews, medical chart abstraction, and process measure analysis. the investigators collected data on patient and clinician experiences with the annie system, including usability, clinical workflow fit, and clinical benefits such as improved hcv medication adherence and rates of appropriately timed lab tests.

Eligibility criteria:
inclusion criteria: * starting hcv treatment at a va clinic * have access/ability to text messaging exclusion criteria: * not being treating for hcv * no access/ability to use a cell phone

Keywords: automated text messaging system implementation science hepatitis c
gluten-free diet in psc and ibd

Conditions: Primary Sclerosing Cholangitis; Ulcerative Colitis; Biliary Tract Diseases; Biliary Disease Tract; Intestinal Disease

Summary: primary sclerosing cholangitis (psc) is a progressive disease of the biliary tree, which represents one of the most frequent indications for orthotopic liver transplantation (oltx) in developed countries. there are several lines of evidence that dietary gluten/gliadin displays chronic pro-inflammatory, lps-like properties. recent evidence demonstrated the protective effect of gluten- free diet (gfd) in autoimmune diseases like type 1 diabetes, irritable bowel syndrome, non-celiac gluten sensitivity and some neurological disorders. this study is intended to explore therapeutic effect of gfd on psc and ibd in prospective self-controlled mono-centric intervention study. hypothesis: avoidance of gluten in diet will reduce progression, symptoms and intestinal inflammation in psc and uc patients.


Eligibility criteria:
inclusion criteria (for psc group): * established diagnosis of psc (based on radiologic features, typical finding on mrcp or ercp) * age 18 - 65 years * alp 1,5x higher than uln * signed informed consent exclusion criteria (for psc group): * patients on gluten-free diet * patients with coeliac disease or wheat allergy * liver transplant recipients * psc/aih overlap syndrome * other causes of liver disease * radiologic or clinical signs of decompensated liver cirrhosis * advanced liver cirrhosis (meld score ˃ 15) * recurrent acute cholangitis or cholangiogenic sepsis in past 3 months * use of antibiotics in past 3 months * history of malignancy * pregnant women * not signed informed consent inclusion criteria (for uc group): * ulcerative colitis diagnosed based on clinical, endoscopic and histological findings * extension of affected colon \> 15cm * mayo score 0-4 * signed informed consent exclusion criteria (for uc group): * cmv, clostridium difficile enterocolitis in past 3 months * use of antibiotics in past 3 months * patients with coeliac disease or wheat allergy * patients on gluten-free diet * pregnant women * not signed informed consent * biologic therapy * methotrexate * prednison \> 10 mg * not signed informed consent

Keywords: primary sclerosing cholangitis cholangitis gluten-free diet ulcerative colitis microbiome
predictive values of preoperative [68ga]ga-psma-11 pet/ct in patients with suspected brain tumours of glial origin

Conditions: Glioma, Malignant; Glioma Glioblastoma Multiforme

Summary: the aim of this study was to analyse usefulness of \[68ga\]ga-psma-11 pet/ct scans in preoperative differentiation between hgg and lgg in patients with suspicion of a tumor of glial origin in previously performed imaging examinations. the pet/ct scan will be compared with postoperative histopathological results and with additional immunohistochemical staining for psma expression.


Eligibility criteria:
inclusion criteria: * primary lesion found in ct/mri with radiological features of glial neoplasm * untreated disease, planned surgery * negative medical history of other neoplastic diseases * age over 18 * informed, voluntary consent to participate in the study exclusion criteria: * pregnant women, breastfeeding women * persons with a known allergy to psma * age under 18 * patient's lack of cooperation

Keywords: glioma psma pet/ct [68ga]ga-psma-11 pet/ct glial tumours
multicenter clinical trial of a phakic implantable collamer® lens (icl)

Conditions: Myopia; Myopic Astigmatism

Summary: this objective of this study is to evaluate the safety, and to collect supportive data on effectiveness of the evo/evo+ visian® implantable collamer® lens (icl) in study participants who have a diagnosis of myopia or myopia with astigmatism. primary study analysis will be evaluated when 300 primary eyes complete 6 months of follow-up. final study analysis will be assessed when all treated eyes complete 36 months of follow-up.

this study will be conducted at up to 20 clinical sites in the united states by surgeons qualified by training and experience to implant staar icls.

Eligibility criteria:
inclusion criteria: * moderate to high myopia or myopic astigmatism correctable with available evo/evo+ icl powers. * stable refractive history within 0.50 d each cylinder and spherical equivalent (se) for 1 year prior to implantation. * able and willing to return for scheduled follow-up examinations after surgery. * able to read, understand and provide written informed consent on the institutional review board (irb)-approved informed consent form (icf) and provide authorization as appropriate for local privacy regulations. * other protocol-specified inclusion criteria may apply. exclusion criteria: * insulin-dependent diabetes or diabetic retinopathy. * history of previous ocular surgery. * cataract of any grade. * monocular. * pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study. * other protocol-specified exclusion criteria may apply.

Keywords: nearsightedness phakic intraocular lens (iol) icl toric icl evo evo+ visian
characterization of visual characteristics in allergic contact dermatitis using the skincam® tool

Conditions: Allergic Contact Dermatitis

Summary: contact dermatitis (cd) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many european countries. the patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. it requires experienced medical staff to read the reaction. newtones technologies society has developed a new tool, the skincam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. this study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the skincam®.

contact dermatitis (cd) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many european countries. allergic contact dermatitis (acd) typically presents as a severe skin inflammation with redness, edema, oozing and crusting. it is characterized by a delayed type iv hypersensitivity response mediated by allergen-specific t cells in sensitized individuals. current diagnosis relies on clinical investigations by diagnostic patch testing with suspected allergenic chemicals. the patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. it requires experienced medical staff to read the reaction. newtones technologies society has developed a new tool, the skincam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. this study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the skincam®.

Eligibility criteria:
inclusion criteria: * patient, male or female, over 18 years of age * patients called for reading patch test, applied 72 or 96 hours ago * patients agreeing to have unidentified photographs of patchs tests * patient affiliated to or benefiting from a social security regime * patient having been informed and not having opposed exclusion criteria: * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant woman

Keywords: allergic contact dermatis (acd) patch test photographs skincams
mechanism and dynamics of bronchial hyper-reactivity to methacholine in distal airway on obese patients with asthma

Conditions: Asthma

Summary: new insights of small airway contribution to asthma have been gained. poor levels of control and recurrent exacerbations were shown to have the phenotypic counterpart of asthma with predominant small airway involvement. very few pathological specificities were identified at this site: mast cells infiltration was suggested as the specific inflammatory change when compared to the proximal airways.biomarkers in asthma are still complex to validate, especially in the blood, since compartmentalisation is intense in the lung and the airways, a property attributed to the filtering role of the lung to maintain homeostasis. over the last few years, fraction exhaled nitric oxide (feno) was developed as a non-invasive and indirect reflection of airway eosinophilic inflammation\]. in the blood, peripheral eosinophil counts were shown as a correct t helper 2 (th2)-phenotype identifier but not perfectly related to airway eosinophilic infiltration. club cell secretory protein (scgb1a1) levels have been shown to have some relevance in asthma, chronic obstructive pulmonary disease (copd), bos, sarcoidosis, and lung cancer.a biomarker for small airway disease in asthma may improve the management of the disease, identify areas of therapeutic resistance and constitute a therapeutic guidance tool. in this study, investigators aimed to assess small airway involvement in asthmatic women as far as they could. for this purpose, investigators analysed trends in air trapping by acquiring expiratory ct slices at each dose during a bronchoprovocation test with metacholine. biomarkers were subsequently tested and confronted to clinical and demographical characteristics in their ability to predict the small airway involvement index obtained at ct.

patients will be recruited in the respiratory department of university hospital in montpellier (france) from june 2012 to march 2014. all patients are asthmatics, in order to avoid any gender-related biases, investigators decided to include only women. all participants had normal range spirometry, specifically regarding forced expiratory volume. each patient will undergo a bronchial provocation test coupled with a thoracic ct scan. bronchial and alveolar nitric oxyde will also be measured, a blood sample will be obtained in order to measure biomarker concentrations, and the patients will be asked to answer the validated asthma control questionnaire in order to quantify asthma control.

Eligibility criteria:
inclusion criteria: * female \>= 18 yrs * asthma * treated with inhaled corticosteroid (ics) * normal range spirometry exclusion criteria: * patients with other respiratory disease * patients with myocardial infarction (for 3 month before enrollment) * patients with cerebrovascular accident (for 3 month before enrollment) * patients with arterial aneurysm known * patients in pregnancy * patients nursing

Keywords: airways asthma overweight
cns qualitative interview

Conditions: Central Nervous System Cancer

Summary: explore factors involved in decision making for patients with new or recurrent cns tumors and their families surrounding treatment planning and clinical trial enrollment.

explore factors involved in decision making for patients with new or recurrent cns tumors and their families surrounding treatment planning and clinical trial enrollment. the team will conduct qualitative interviews with a diverse group of patients and families considering treatment for new and recurrent cns tumors to determine challenges surrounding treatment and study enrollment that may be modifiable through community, hospital, and university of colorado cancer center resources. the team will then assess the impact of these resources on decision making through follow-up interviews.

Eligibility criteria:
inclusion criteria: 1. be the parent or caregiver of a child or young adult receiving treatment at chco a. child must meet one criterion below: i. newly diagnosed with a cns tumor ii. relapse of a cns tumor requiring further therapy. therapy may be standard of care of dictated by an open clinical trial 2. patient 18 years of age or older a. must meet one of the criteria below: i. newly diagnosed with a cns tumor ii. relapse of a cns tumor requiring further therapy. therapy may be standard of care of dictated by an open clinical trial exclusion criteria: * does not meet inclusion criteria
a study to validate the safety and feasibility of artisential in colorectal cancer surgery using prospectively constructed multi-center registry

Conditions: Rectal Cancer; Rectosigmoid Cancer; Rectosigmoid Junction Cancer

Summary: this study is to validate the safety and feasibility of artisential (articulating laparoscopic instrument) colorectal surgery and compare it with robotic surgery for patients with rectal cancer and rectosigmoid junction cancer.


Eligibility criteria:
inclusion criteria: * age : 18 \~ 80 year old male or female * biopsy-proven adenocarcinoma * rectal cancer or rectosigmoid junction cancer * primary cancer * non-metastatic cancer * planned (or elective) curative resection * low anterior resection with double-stapled technique exclusion criteria: * preoperative systemic chemotherapy * distant metastasis at initial diagnosis * palliative surgery * emergent surgery * lynch syndrome or fap-associated cancer

Keywords: laparoscopic surgery minimally invasive surgery robotic-assisted surgery robotic surgery da vinci system artisential articulating laparoscopic instrument